Loading
SOS1 (Son of sevenless homolog 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Skin cancer, Breast cancer and 1 more.
Promotes the exchange of Ras-bound GDP by GTP. Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3/ERK1 in response to EGF. Catalytic component of a trimeric complex that participates in transduction of signals from Ras to Rac by promoting the Rac-specific guanine nucleotide exchange factor (GEF) activity.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes affected pathway 0.83, literature 0.94, genetic association 0.00, somatic mutation 0.91, animal model 0.38). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Endometrial Carcinoma.
In plain words · SOS1 (Son of sevenless homolog 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Skin cancer, Breast cancer and 1 more.
SOS1 (Son of sevenless homolog 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Skin cancer, Breast cancer and 1 more.
Promotes the exchange of Ras-bound GDP by GTP. Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3/ERK1 in response to EGF.
No product in this corpus aims at SOS1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA SOS1: RNA low tissue specificity; no normal tissue stained high; highest cancer staining melanoma (3 of 11 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Endometrial cancer, Skin cancer (all types), Breast cancer (all types), Gastric & gastro-oesophageal junction cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q07889; CIViC gene SOS1; IntOGen SOS1; Human Protein Atlas SOS1 tissue; Open Targets ENSG00000115904 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Chardin et al, Science, 1993, "Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2". Source.
Sources: HGNC HGNC:11187 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q07889 (protein name, function text, keywords and locations (REST API)); CIViC gene SOS1 (1 evidence items, 0 assertions, 1 variants; diseases: (GraphQL API, CC0)); Open Targets ENSG00000115904 (association with cancer (MONDO_0004992) 0.80; per-cancer scores at or above 0.5: gastric cancer 0.51, endometrial cancer 0.53, skin cancer 0.56, breast cancer 0.53 (GraphQL API, CC0)); IntOGen SOS1 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Promotes the exchange of Ras-bound GDP by GTP. Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3/ERK1 in response to EGF. Catalytic component of a trimeric complex that participates in transduction of signals from Ras to Rac by promoting the Rac-specific guanine nucleotide exchange factor (GEF) activity. Locus 2p22.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
Medium only: breast cancer, cervical cancer, endometrial cancer, head and neck cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SOS1" OR ABSTRACT:"SOS1" OR TITLE:"SOS Ras/Rac guanine nucleotide exchange factor 1" OR ABSTRACT:"SOS Ras/Rac guanine nucleotide exchange factor 1" OR TITLE:"Son of sevenless homolog 1" OR ABSTRACT:"Son of sevenless homolog 1" OR TITLE:"GF1" OR ABSTRACT:"GF1" OR TITLE:"GINGF" OR ABSTRACT:"GINGF") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SOS1, not a curated reading list.
Shares RAS / RAF / MEK / ERK (MAPK), Gastric & gastro-oesophageal junction cancer, Breast cancer (all types).
Shares RAS / RAF / MEK / ERK (MAPK), Gastric & gastro-oesophageal junction cancer.
Shares RAS / RAF / MEK / ERK (MAPK), Skin cancer (all types), CIViC, IntOGen.
Shares RAS / RAF / MEK / ERK (MAPK), Gastric & gastro-oesophageal junction cancer.